Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy.
The identification of tumor-associated antigens has suggested new possibilities for cancer therapy. However, multiple mechanisms may contribute to the ability of tumor to escape antitumor immune responses. Tumor antigen heterogeneity, modulation of HLA expression and immune suppressive mechanisms may occur at any time during tumor cell progression, and can affect the outcome of therapeutic immune intervention. In particular, the appearance of altered HLA class I phenotypes during tumor development may have important biological and medical implications due to the role of these molecules in T and NK cell functions. Exhaustive tumor tissue studies are necessary before deciding whether a particular patient is suitable for inclusion in T cell-based immunotherapy protocols.
Ruiz-Cabello
Francisco
F
Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain. fgarrido@hvn.sas.cica.es
Cabrera
Teresa
T
Lopez-Nevot
Miguel-Angel
MA
Garrido
Federico
F
D000954:Antigens, Surface / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000954:Antigens, Surface